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Abstract
Background: 3,3'-Diindolylmethane (DIM), an indole derivative produced in the stomach after the
consumption of broccoli and other cruciferous vegetables, has been demonstrated to exert anti-
cancer effects in both in vivo and in vitro models. We have previously determined that DIM (0 – 30
μmol/L) inhibited the growth of HT-29 human colon cancer cells in a concentration-dependent
fashion. In this study, we evaluated the effects of DIM on cell cycle progression in HT-29 cells.
Methods: HT-29 cells were cultured with various concentrations of DIM (0 – 30 μmol/L) and the
DNA was stained with propidium iodide, followed by flow cytometric analysis. [3H]Thymidine
incorporation assays, Western blot analyses, immunoprecipitation and in vitro kinase assays for
cyclin-dependent kinase (CDK) and cell division cycle (CDC)2 were conducted.
Results: The percentages of cells in the G1 and G2/M phases were dose-dependently increased
and the percentages of cells in S phase were reduced within 12 h in DIM-treated cells. DIM also
reduced DNA synthesis in a dose-dependent fashion. DIM markedly reduced CDK2 activity and
the levels of phosphorylated retinoblastoma proteins (Rb) and E2F-1, and also increased the levels
of hypophosphorylated Rb. DIM reduced the protein levels of cyclin A, D1, and CDK4. DIM also
increased the protein levels of CDK inhibitors, p21CIP1/WAF1 and p27KIPI. In addition, DIM reduced
the activity of CDC2 and the levels of CDC25C phosphatase and cyclin B1.
Conclusion: Here, we have demonstrated that DIM induces G1 and G2/M phase cell cycle arrest
in HT-29 cells, and this effect may be mediated by reduced CDK activity.
Background
Epidemiologic data continue to support the hypothesis
that the intake of Brassica plants, including turnips, kale,
broccoli, cabbage, Brussels sprouts, and cauliflower, may
exert protective effects against various types of cancers [1-
4]. Dietary glucosinolates present in Brassica species have
been previously shown to protect against several types of
cancer [5,6]. Indole-3-carbinol (I3C) is the principal
hydrolysis product of the glucosinolate glucobrassicin [7],
and has been shown to offer significant protection against
cancer in animal models induced by a variety of chemical
carcinogens [8-10], as well as in cultured human cancer
cells [11-13]. Initial clinical trials in women have shown
that I3C may prove to be a promising agent against cervi-
cal and breast cancers (reviewed in [14]).
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I3C is chemically unstable in the low pH environment of
the stomach, and has been demonstrated to undergo self-
condensation reactions, resulting in the production of a
variety of polymeric products. Among them, 3,3'-diin-
dolylmethane (DIM) is a principal product, which is acid-
stable [15,16] and is measurable in both human urine
samples [17] and animal tissues [18]. It has been shown
that DIM reduces carcinogenesis in a variety of animal
cancer models, including the tumor growth of injected
TRAMP-C2, a mouse prostate cell line, in C57BL/6 mice
[19], 7,12-dimethylbenz [a]anthracene (DMBA)-induced
mammary tumors in rats [20], benzo [a]pyrene-induced
stomach cancers in mice, and the growth of transplantable
human breast carcinoma and angiogenesis in mice [21].
In addition, results generated with in vitro cell culture
studies have shown that DIM inhibits the proliferation of
a variety of cancer cell types, including prostate (Reviewed
in [22]) and breast [23,24] cancer cells, via the induction
of cell cycle arrest and apoptosis.
Carcinogenesis is a multistep process, and there are sev-
eral opportunities for intervention to halt, regress, or
delay the carcinogenic process. One of these anti-carcino-
genic actions involves the inhibition of cell cycle progres-
sion, because insensitivity to growth-inhibitory
(antigrowth) signals is one of the hallmarks of cancer
[25]. Therefore, searching for bioactive food components
with the ability to inhibit cancer cell cycle progression
should facilitate the identification of new compounds
that can potentially inhibit cancer progression.
Cell cycle progression depends on the activation of cyclin-
dependent kinases (CDK), which act consecutively in G1
to initiate S phase and in G2 to initiate mitosis. Upon
mitogenic stimuli, D-type cyclins are induced and bind to
and activate CDK4 and CDK6. The cyclin D-dependent
kinases initiate the phosphorylation of retinoblastoma
proteins (Rb), relieving E2F from negative restraints and
allowing for the expression of certain E2F-target genes.
Cyclin E-CDK2 completes Rb phosphorylation, further
permitting the activation of E2F-responsive genes. CDK2
is also capable of binding to A-type cyclins during the S
phase, whereas the control of G2 and M phases depends
principally upon the cyclin A-cell division cycle (CDC)2
and cyclin B-CDC2 (reviewed in [26,27]). Several mam-
malian CDK inhibitors (CDKIs) have been previously
identified. One group is the INK4 (inhibitors of CDK4)
family, which has four members–p16INK4a, p15INK4b,
p18INK4c and p19INK4d–all of which share the ability to
control the G1/S transition [28,29]. The second group of
CDKIs includes p21CIP1/WAF1 and p27KIPI. These proteins
conduct pivotal functions in cell cycle regulation via the
coordination of internal and external signals that inhibit
cell cycle progression at critical checkpoints [29].
There have been only a few studies conducted thus far that
have assessed the effects of DIM on the prevention of
colon cancer. DIM has been shown to effect a dose-
dependent cytotoxicity in HT-29 human colon adenocar-
cinoma cells [30]. We have previously demonstrated that
DIM inhibits the growth of HT-29 and HCT-116 human
colon cancer cells and induced apoptosis in these cells
[31]. To the best of our knowledge, the molecular mecha-
nisms by which DIM inhibits the cell cycle progression of
colon cancer cells have yet to be clearly elucidated. The
results of this study show that DIM delays cell cycle pro-
gression at the G1 and G2/M phases and inhibits the activ-
ity of CDK2 and CDC2 in HT-29 cells.
Methods
Materials
The following reagents and chemicals were obtained from
the indicated suppliers: DIM (LKT Laboratories, St. Paul,
MN); anti-β-actin and p16INK/CDKN2  (Sigma, St. Louis,
MO); antibodies against CDC25C, cyclin B1, and phos-
pho-Rb (Cell Signaling, Danvers, MA); horseradish perox-
idase (HRP)-conjugated anti-rabbit and anti-mouse IgG
and protein A-Sepharose (GE Healthcare Biosciences, Pis-
cataway, NJ); [γ-32P]ATP (Perkin Elmer Life Science,
Waltham, MA); anti-cyclin D1 antibody (Neomarkers,
Fremont, CA); and antibodies against p21CIP1/WAF1,
p27KIPI, cyclin A, cyclin E, CDK2, CDK4, CDC2, E2F-1,
and Rb (Santa Cruz Biotechnology, Santa Cruz, CA).
Cell culture
The HT-29 cell line was obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and main-
tained in DMEM/F-12 supplemented with 10% FBS,
100,000 U/L of penicillin, and 100 mg/L of streptomycin.
In order to determine the effects of DIM, we plated the
cells with DMEM/F12 containing 10% FBS. Prior to DIM
treatment, the cell monolayers were rinsed and serum-
deprived for 24 h with DMEM/F-12 containing 1% FBS.
After serum deprivation, we replaced the medium with
fresh serum deprivation medium with or without 30
μmol/L of DIM.
To evaluate [3H]thymidine incorporation, HT-29 cells
were plated in 96-well plates at a density of 6,000 cells/
well, serum-deprived, and treated with various concentra-
tions of DIM for 9 h, as described above. 0.5 μCi [3H]thy-
midine was then added to each well, and the incubation
continued for an additional 3 h at 37°C. The incorpora-
tion of [3H]thymidine into the DNA of HT-29 cells was
determined as previously described [32].
Cell cycle analysis by flow cytometry
Cells were plated in 100 mm dishes at 2,000,000 cells/
dish in DMEM/F-12 containing 10% FBS. The cells wereBMC Gastroenterology 2009, 9:39 http://www.biomedcentral.com/1471-230X/9/39
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serum-deprived and treated for 12 h with various concen-
trations of DIM, then trypsinized. The nuclei were stained
with propidium iodide as described previously [33] and
subjected to fluorescence-activated cell sorting analysis
utilizing the FACScan system (Becton Dickinson, Franklin
Lakes, NJ). The data were analyzed using ModFit V.1.2.
software.
Immunoprecipitation and immunoblot analyses
The cells were lysed as previously described [34] and the
protein concentrations of lysates were determined using a
bicinchoninic acid protein assay kit (Thermo Fisher Scien-
tific, Rockford, IL). For immunoprecipitation, cell lysates
(750 μg protein) were precleared with 1.5 μg of normal
rabbit IgG and 100 μL of protein A-Sepharose bead slurry
on a rotating platform for 1 h, then centrifuged for 10 min
at 12,000 rpm at 4°C. The supernatants were incubated
for 1 h with 1 μg of anti-CDK2 or anti-CDC2 antibody at
4°C. The protein A-Sepharose was added and incubated
for an additional 1 h at 4°. The beads were then washed
four times in lysis buffer via 5 min of centrifugation at
2,500 rpm at 4°C. Total cell lysates (50 μg protein) or
immunoprecipitated proteins were resolved on SDS-
PAGE (4 – 20% or 10 – 20%) and transferred onto a pol-
yvinylidene fluoride membrane (Millipore, Billerica,
MA). The blots were incubated for 1 h with anti-CDK2
(1:1000), anti-CDK4 (1:1000), anti-cyclin A (1:1000),
anti-cyclin D1 (1:200), anti-cyclin E (1:1000), anti-
p21CIP1/WAF1  (1:1000), anti-p27KIP1(1:1000), anti-phos-
pho-Rb (1:1000), anti-Rb (1:1000), anti-E2F-1 (1:1000),
or anti-β-actin (1:2000) antibody. The membranes were
then incubated with anti-mouse or anti-rabbit HRP-con-
jugated antibody. The signal was detected with a chemilu-
minescence detection system (Millipore). Densitometric
analysis was conducted using the Bio-profile Bio-ID appli-
cation (Vilber-Lourmat, Marne-la-Vallée, France). Expres-
sion levels were normalized to β-actin and the control (0
μmol/L DIM at 2 h) levels were set at 100%.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated using Tri reagent (Sigma), and
cDNA was synthesized using 2 μg of total RNA with Super-
Script™ II reverse transcriptase (Invitrogen, Carlsbad, CA),
as described previously [35]. For cDNA amplification,
primers for human p21CIP1/WAF1 (upstream primer; 5'-AAR
AAG GAA GCG ACC TGC AA-3'; downstream primer, 5'-
CCA ACG CTT TTA GAG GCA GA-3', annealing at 55°C
for 1 min with 38 cycles), p27KIP1 (upstream primer; 5'-
AAT AAG GAA GCG ACC TGC AA-3'; downstream primer,
5'-CAA ACG CTT TTA GAG GCA GA-3', annealing at 60°C
for 1 min with 27 cycles), and p16INK/CDKN2 (upstream
primer; 5'-GCC CAA CGC ACC GAA TAG-3'; downstream
primer, 5'-ACG GGT CGG GTG AGA GTG-3', annealing at
54°C for 1 min with 37 cycles) were used. The expressions
of human β-actin transcripts were assessed as an internal
control, as described previously [34]. For each combina-
tion of primers, the kinetics of the PCR amplification were
studied, the number of cycles corresponding to the pla-
teau was determined, and the PCR was conducted within
the exponential range. The PCR products were then sepa-
rated in 1 or 2% agarose gel and stained with ethidium
bromide. Bands corresponding to each specific PCR prod-
uct were quantified via the densitometric scanning of the
exposed film using the Bio-profile Bio-ID application.
In vitro kinase assay
Cell lysates (750 μg protein) were immunoprecipitated
with polyclonal antibody against CDK2 or CDC2 as
described above. After capture with protein A-Sepharose
and subsequent washes, the beads were incubated for 30
min at 37°C in 15 μL of kinase buffer [36] containing 2
μg of histone H1 (Roche, Nutley, NJ) and 3 μCi of [γ-
32P]ATP (CDK2 kinase assay) or in 30 μL of kinase buffer
containing 2 μg of histone H1 and 5 μCi of [γ-32P]ATP
(CDC2 kinase assay). The reaction was halted by boiling
the samples for 5 min in SDS sample buffer. The 32P-
labeled histone H1 was resolved on SDS-PAGE, and the
gels were dried and subjected to autoradiography. Signals
were quantified via densitometric scanning of the exposed
film.
Statistical analysis
The results were expressed as the means ± SEM for the
indicated number of separate experiments. Statistical data
analysis was conducted with ANOVA. Differences
between the treatment groups were analyzed via Duncan's
multiple range test or Student's t-test. Differences were
considered significant at P < 0.05. Statistical analyses were
conducted using the SAS system for Windows, version
8.12.
Results
DIM induces cell cycle arrest at the G1 and G2/M phases 
and inhibits DNA synthesis in HT-29 cells
We have previously shown that DIM reduces the numbers
of viable HT-29 cells in a dose-dependent manner (10 –
30 μmol/L) [31]. We have also reported that these concen-
trations of DIM do not affect the viability of IEC-6 cells,
which are normal small intestinal epithelial cells [31]. To
determine whether DIM regulates cell cycle progression in
HT-29 cells, the cells were treated for 12 h with 10 – 30
μmol/L of DIM, and the DNA was stained with propidium
iodide, followed by FACS analysis. The treatment of cells
with various concentrations of DIM for 12 h resulted in
dose-dependent increases in the percentage of cells in G1
and G2/M phases with a concomitant reduction in cell
numbers in the S phase (Fig. 1A). However, the differ-
ences between 0 and 10 μmol/L of DIM in G1 and S phase
were not statistically significant. Consistent with the
occurrence of cell cycle G1 arrest at 12 h, DIM reduced the
[3H]thymidine incorporation into the DNA of HT-29 cells
in a dose-dependent manner (Fig. 1B).BMC Gastroenterology 2009, 9:39 http://www.biomedcentral.com/1471-230X/9/39
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DIM induces cell cycle arrest at G1 or G2/M phases and inhibits [3H]thymidine incorporation in HT-29 cells Figure 1
DIM induces cell cycle arrest at G1 or G2/M phases and inhibits [3H]thymidine incorporation in HT-29 cells. (A) 
Cells were plated in 6-well plates at 200,000 cells/well with DMEM/F12 supplemented with 10% FBS. 24 h after plating, the 
monolayers were serum-deprived for 24 h with DMEM/F-12 containing 1% FBS. After serum deprivation, cells were incubated 
for 12 h in serum deprivation medium containing 10, 20 or 30 μmol/L DIM. The nuclei were stained with propidium iodide and 
the cell cycle was analyzed via flow cytometry. (B) Cells were plated at a density of 6,000 cells/well in 96-well plates and serum-
deprived, then incubated for 9 h in serum deprivation medium containing 0, 10, 20 or 30 μmol/L DIM. [3H]Thymidine was 
added, and the cells were incubated for an additional 3 h to measure the incorporation into DNA. Each bar represents the 
mean ± SEM (n = 6). Comparisons between groups that yielded significant differences (P < 0.05) are indicated by different let-
ters above each bar.
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DIM reduces the levels of CDK4, cyclin A, and cyclin D1 
proteins
We first examined the effects of DIM on proteins control-
ling the G1/S phase transition. DIM did not affect the lev-
els of the CDK2 protein, whereas the levels of CDK4 were
reduced in HT-29 cells within 2 h after treatment with 30
μmol/L DIM. The levels of cyclin A and cyclin D1 were
reduced within 6 h and 2 h, respectively, after treatment
with 30 μmol/L of DIM, whereas the levels of cyclin E
were not altered by DIM treatment (Fig. 2).
DIM increases the levels of p21 and p27 proteins and 
mRNAs
Because the CDK inhibitors p21CIP1/WAF1 and p27KIP1 are
known to inhibit CDK activity, we subsequently exam-
ined the effects of DIM on the levels of p21CIP1/WAF1 and
p27KIP1 proteins. The levels of p21CIP1/WAF1 and p27KIP1
proteins were markedly increased in HT-29 cells at 6 h
after treatment with 30 μmol/L of DIM (Fig. 3A). In order
to determine whether DIM regulates the levels of p21CIP1/
WAF1and p27KIP1 at the RNA level, we conducted RT-PCR
analyses. The mRNA levels of p21CIP1/WAF1 and p27KIP1
increased within 2 h after treatment with 30 μmol/L of
DIM, which were consistently higher during the 12 h of
DIM treatment (Fig. 3B). We also examined the effects of
DIM on the levels of p16INK/CDKN2  (also known as
p16INK4a) protein and mRNA. The levels of p16INK/CDKN2
protein and mRNA were not affected by DIM treatment
(Fig. 3A and 3B).
DIM reduces the levels of CDK4 and of cyclin A and E in HT-29 cells Figure 2
DIM reduces the levels of CDK4 and of cyclin A and E in HT-29 cells. Cells were treated with DIM as described in Fig-
ure 1A. Cell lysates were analyzed via Western blotting with the indicated antibodies. Photographs of the chemiluminescent 
detection of the blots, which were representative of three independent experiments, are shown. The relative abundance of 
each band to its own β-actin was quantified, and the control levels were set at 100%. The adjusted mean ± SEM (n = 3) of each 
band is shown above each blot. *Significantly different from 0 μmol/L DIM, P <0.05.
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DIM increases the levels of p21 and p27 proteins and mRNAs in HT-29 cells Figure 3
DIM increases the levels of p21 and p27 proteins and mRNAs in HT-29 cells. Cells were treated with different con-
centrations of DIM as described in Figure 1. (A) Cell lysates were analyzed by Western blotting with the indicated antibodies. 
Photographs of the chemiluminescent detection of the blots, which were representative of three independent experiments, are 
shown. (B) Total RNA was isolated and reverse-transcribed, and PCR was performed with the specific primers for p16, p21, 
p27, or β-actin. PCR products were separated in an agarose gel with TAE buffer and stained with ethidium bromide. Photo-
graphs of the ethidium bromide-stained gels, which are representative of three independent experiments, are shown. The rela-
tive abundance of each band to its own β-actin was quantified, and the control levels were set at 100%. The adjusted mean ± 
SEM (n = 3) of each band is shown above each blot. *Significantly different from 0 μmol/L DIM, P < 0.05.
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DIM inhibits the activity of CDK2 and the levels of 
phospho-Rb and increases those of hypophosphorylated 
Rb
In order to determine whether the reduced cyclin A and
increased p21CIP1/WAF1  and p27KIP1  protein expressions
induced by DIM treatment resulted in the inhibition of
CDK2 activity, total cell lysates were immunoprecipitated
with the CDK2 antibody followed by in vitro kinase assays,
using histone H1 as the substrate. A reduction in CDK2
activity was detected within 2 h after treatment with 30
μmol/L of DIM, with a significant difference becoming
apparent during 12 h of DIM treatment (Fig. 4A).
Members of the Rb protein family are phosphorylated by
CDKs, resulting in the activation of gene expression
required for cell cycle progression. Because DIM inhibited
CDK2 activity, we subsequently attempted to determine
whether the reduction in CDK activity induced by DIM
treatment led to reduced phosphorylation of the Rb pro-
tein. Western blot analysis of total cell lysates with phos-
pho-Rb antibody revealed that phospho-Rb levels were
reduced in the DIM-treated cells. When the immunoblot
was probed using total Rb antibody, two bands were
detected with an increase in the intensity of the lower
band (hypophosphorylated Rb) being detected in the
DIM-treated HT-29 cells, whereas the intensity of the
higher band (hyperphosphorylated Rb) was reduced by
DIM treatment. The levels of the E2F-1 protein were sig-
nificantly lower in the cells treated with DIM for 12 h (Fig.
4B).
DIM inhibits CDC2 activity
To elucidate the mechanisms by which DIM induces G2/
M arrest, the levels of G2/M regulatory proteins were
assessed. The protein levels of cyclin B1 and CDC25C
were reduced in cells treated with 30 μmol/L of DIM at 6
h and 2 h, respectively. DIM had no effect on the levels of
the CDC2 protein (Fig. 5A). In vitro kinase assays were
conducted to assess CDC2 activity after pulling down the
CDC2 immune complex with CDC2 antibody. CDC2
kinase activity was reduced significantly at 6 h after the
addition of DIM (Fig. 5B).
Discussion
Preliminary clinical trials in women suggest that the I3C
found in cabbage, broccoli, Brussels sprouts, and cauli-
flower is a promising agent against breast and cervical can-
cer (reviewed in [14]). I3C has been observed to reduce
the development of cancer in animals when administered
prior to or simultaneously with a carcinogen, whereas it
enhanced the development of cancer when administered
after carcinogen treatment (Reviewed in [5]). For exam-
ple, Plate et al. reported that I3C reduced azoxymethane
(AOM)-induced aberrant crypt foci formation in rats [37],
whereas Suzui et al. observed that I3C increased the tumor
multiplicity of adenocarcinomas in the colon of AOM-
treated rats [38]. Because it is believed that DIM mediates
the anticarcinogenic effects of I3C, it is important to
understand the mechanisms by which DIM exerts its anti-
carcinogenic effects.
In our previous study, we demonstrated that DIM inhibits
cell growth and induces apoptosis in HT-29 and HCT-116
human colon cancer cells in a concentration-dependent
manner (10–30 μmol/L). However, unpublished results
in our laboratories showed that I3C at the same concen-
trations did not alter the viable cell numbers of either HT-
29 human colon cancer or DU145 human prostate cancer
cells (Kim EJ and Park JHY, unpublished results). In the
present study, using HT-29 cells, we have shown that 1)
DIM induces G1 and G2/M arrest; 2) DIM reduces the
protein levels of cyclin A, D1, and CDK4. 3) DIM
increased the protein levels of the CDK inhibitors,
p21CIP1/WAF1 and p27KIP1; 4) DIM reduced the phosphor-
ylation of Rb and the levels of E2F-1, as well as CDK2
activity; 5) DIM reduced the levels of CDC25C phos-
phatase and cyclin B1, as well as CDC2 activity. Hanahan
and Weinberg [25] described six necessary changes in cell
physiology that dictate malignant growth, two of which
are the self-sufficiency of growth signals and the evasion
of programmed cell death or apoptosis. Therefore, a bio-
active compound such as DIM, which has the ability to
induce apoptosis and inhibit cell cycle progression in
colon cancer cells, may potentially be utilized as a chem-
opreventive agent for colon cancer. More studies with ani-
mal models and humans will be necessary to further
determine whether DIM might potentially prove useful as
an agent to prevent the development of colon cancer.
There is currently a dearth of data regarding the pharma-
cokinetics of DIM and its tissue distribution in humans
[39]. Therefore, it is difficult to extrapolate the findings of
the present study to humans. In this study, we utilized
DIM at a concentration of 10 – 30 μmol/L, and Hong et al.
[24] previously assessed the effects of 10 – 100 μmol/L
DIM on cell cycle progression in breast cancer cells. We
demonstrated, in a previous study, that DIM at concentra-
tions of 10 – 30 μmol/L had no effect on the growth of
IEC-6 cells, a normal intestinal epithelial cell line derived
from the rat jejunum [31]. DIM was detected in the
plasma (0.8 μg/mL or 3.24 μmol/L) and liver tissue (4 μg/
mL or 16.3 μmol/L) of CD-1 female mice 2 h after the oral
administration of 250 mg/kg of I3C [40]. In a phase I trial
of I3C, DIM was reported to be the only detectable com-
pound and reached a level of 607 ng/mL (2.46 μmol/L)
after the administration of a single dose of 1000 mg [41].
Therefore, it is possible that the concentrations of DIM in
the plasma and tissues of mice can be increased to the lev-
els employed in our current study. It is also possible that
low gut uptake of DIM may produce elevated DIM con-BMC Gastroenterology 2009, 9:39 http://www.biomedcentral.com/1471-230X/9/39
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centrations in the lumen of the colon, which can be made
available to the colonocytes. It remains to be determined
whether the concentrations of DIM utilized in the present
study are clinically pertinent, by determining the concen-
trations of DIM in human plasma or the colonic lumen
after the chronic administration of I3C and/or DIM.
The mammalian cell cycle is regulated by CDKs. CDK4
and 6 initiate the phosphorylation of Rb, which is aug-
mented by the activity of CDK2 complexes with cyclins A
and E. The Rb family proteins bind to members of the E2F
transcription factor family and block the E2F-dependent
transcription of genes controlling the G1 to S phase tran-
DIM inhibits CDK2 activity and reduces the levels of phospho-Rb and E2F-1 in HT-29 cells Figure 4
DIM inhibits CDK2 activity and reduces the levels of phospho-Rb and E2F-1 in HT-29 cells. Cells were treated 
with different concentrations of DIM as described in Figure 1. (A) CDK2 was immunoprecipitated and analyzed via an in vitro 
kinase assay using histone H1 as a substrate. An autoradiograph of the dried gel, which is representative of three independent 
experiments, is shown. (B) Cell lysates were analyzed via Western blotting. Photographs of the chemiluminescent detection of 
the blots, which were representative of three independent experiments, are shown. The relative abundance of each band to its 
own CDK2 (A) or β-actin (B) was quantified, and the control levels were set at 100%. The adjusted mean ± SEM (n = 3) of 
each band is shown above each blot. *Significantly different from 0 μmol/L DIM, P < 0.05.
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sition and subsequent DNA synthesis [42]. The phospho-
rylation of Rb disrupts its association with E2F, thereby
reducing the suppression of E2F target genes (reviewed in
[43]). In the current study, DIM drastically reduced the
levels of CDK4 and cyclin D1 and increased the levels of
p21CI1/CIP1  and p27KIP1  proteins, thus suggesting that
CDK4 activity may have been reduced in the DIM-treated
cells. We also noted that DIM inhibited CDK2 activity and
Rb phosphorylation. In addition to the observed reduc-
tion in Rb phosphorylation, DIM induced a reduction in
the levels of the E2F-1 protein. These findings indicate
that the expression of Rb-E2F regulatory targets may have
DIM reduces the protein levels of cyclin B1 and CDC25C and the activity of CDC2 in HT-29 cells Figure 5
DIM reduces the protein levels of cyclin B1 and CDC25C and the activity of CDC2 in HT-29 cells. Cells were 
treated with different concentrations of DIM as described in Figure 1. (A) Cell lysates were analyzed via Western blotting with 
the indicated antibodies. Photographs of the chemiluminescent detection of the blots, which were representative of three inde-
pendent experiments, are shown. (B) CDC2 was immunoprecipitated and analyzed by an in vitro kinase assay, using histone H1 
as a substrate. Photographs of an autoradiograph of the dried gel, which are representative of three independent experiments, 
are provided. The relative abundance of each band to its own β-actin (A) or CDC2 (B) was quantified, and the control levels 
were set at 100%. The adjusted mean ± SEM (n = 3) of each band is shown above each blot. *Significantly different from 0 
μmol/L DIM, P < 0.05.
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been reduced in DIM-treated cells, and this phenomenon
may have contributed to DIM-induced G1 arrest in HT-29
cells.
p21CIP1/WAF1 expression is usually controlled at the tran-
scriptional level by both p53-dependent and -independ-
ent mechanisms [44]. In the present study, we noted that
DIM induced p21CIP1/WAF1 mRNA levels in HT-29 cells
(Fig. 3), which harbor a mutant p53 gene [45]. In addi-
tion, in our previous study, we demonstrated that p53 lev-
els were not affected by DIM treatment in HCT116 human
colon cancer cells, which harbor the wild-type p53 gene
[31]. These results show that DIM increases p21CIP1/WAF1
levels via p53-independent mechanisms.
Entry into mitosis is regulated by the activity of the cyclin
B/CDC2 complex, which is tightly controlled by its phos-
phorylation status. CDC2 is inactive in phosphorylated
form, and the CDC25C phosphatase removes the phos-
phates of Thr14 and Tyr15 in CDC2, resulting in the acti-
vation of the cyclinB/CDC2 complex (Review in [46]). In
the current study, DIM caused a reduction in the levels of
cyclin B1 and CDC25C proteins, an effect which may have
contributed to reduced CDC2 activity, ultimately leading
to G2/M cell cycle delay.
Conclusion
We have demonstrated that DIM inhibits HT-29 cell pro-
liferation and induces G1 and G2/M phase arrest, both of
which are associated with reduced CDK2 and CDC2 activ-
ity, respectively. The current results, together with the
results of our previous work [31], show that DIM inhibits
colon cancer cell growth via the induction of cell cycle
arrest and apoptosis. Future animal and human studies
will be required to determine whether DIM can be applied
as a potential agent for the prevention of colon cancer.
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